On Tuesday, Verve Therapeutics Inc (NASDAQ: VERV) was -3.99% down from the session before settling in for the closing price of $6.26. A 52-week range for VERV has been $6.02 – $21.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 126.44% over the past five years. When this article was written, the company’s average yearly earnings per share was at 8.01%. With a float of $54.79 million, this company’s outstanding shares have now reached $81.97 million.
Let’s look at the performance matrix of the company that is accounted for 255 employees.
Verve Therapeutics Inc (VERV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verve Therapeutics Inc stocks. The insider ownership of Verve Therapeutics Inc is 30.25%, while institutional ownership is 72.38%. The most recent insider transaction that took place on Apr 02 ’24, was worth 12,475. In this transaction Chief Administrative Officer of this company sold 1,514 shares at a rate of $8.24, taking the stock ownership to the 8,659 shares. Before that another transaction happened on Nov 29 ’23, when Company’s Chief Financial Officer sold 554 for $11.45, making the entire transaction worth $6,343. This insider now owns 4,060 shares in total.
Verve Therapeutics Inc (VERV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 8.01% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
You can see what Verve Therapeutics Inc (VERV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.13, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -3.10 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Verve Therapeutics Inc (NASDAQ: VERV) saw its 5-day average volume 0.99 million, a negative change from its year-to-date volume of 1.22 million. As of the previous 9 days, the stock’s Stochastic %D was 10.32%. Additionally, its Average True Range was 0.65.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 0.39%, which indicates a significant decrease from 2.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.78% in the past 14 days, which was lower than the 97.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.36, while its 200-day Moving Average is $12.98. Nevertheless, the first resistance level for the watch stands at $6.23 in the near term. At $6.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.59. If the price goes on to break the first support level at $5.87, it is likely to go to the next support level at $5.74. The third support level lies at $5.52 if the price breaches the second support level.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are 83,619K outstanding shares of the company, which has a market capitalization of 472.09 million. As of now, sales total 11,760 K while income totals -200,070 K. Its latest quarter income was 5,140 K while its last quarter net income were -48,350 K.
